Whether peptides are legal in the United States depends on which act is being asked about: whether the molecule is a controlled substance, who the drug law regulates, selling one as research material, prescribing an approved product, compounding one, importing one, or using one in sport. As of September 21, 2026, the Controlled Substances Act's anabolic-steroid definition names no peptide, and we have not found a state statute that bans research peptides as a class. What federal law does regulate is intent: a peptide sold or promoted for use in a person is a drug under the Federal Food, Drug, and Cosmetic Act, and an unapproved drug cannot lawfully be introduced into interstate commerce.

Seven questions hiding inside one

Are peptides controlled substances?

No. The Controlled Substances Act reaches "anabolic steroids," defined at 21 U.S.C. 802(41)(A) as "any drug or hormonal substance, chemically and pharmacologically related to testosterone (other than estrogens, progestins, corticosteroids, and dehydroepiandrosterone)," followed by a list of named steroid compounds. A peptide is a chain of amino acids joined by amide bonds. It is not chemically related to testosterone, which is a four-ring sterane, and no peptide appears in that definition; are peptides steroids sets the two structures side by side. The word "peptide hormones" that athletes see on the WADA list is a sporting category, not a chemical kinship with steroids and not a scheduling decision.

The FD&C Act, not the Controlled Substances Act, is the statute that governs this market.

What the FD&C Act actually regulates

Federal drug law turns on a definition. Under 21 U.S.C. 321(g)(1) the term "drug" includes:

articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals; and (C) articles (other than food) intended to affect the structure or any function of the body of man or other animals21 U.S.C. 321(g)(1), FD&C Act section 201(g)(1)

Two words carry the weight: "intended for." A vial of lyophilized peptide is a chemical. It becomes a drug when someone intends it for use in a body, and the same molecule can be a drug on one website and a research chemical on another. Once an article is a drug, section 201(p) asks whether it is a "new drug," meaning one that is not generally recognized among qualified experts as safe and effective for the uses suggested in its labeling. Section 505(a), at 21 U.S.C. 355(a), then states the rule:

No person shall introduce or deliver for introduction into interstate commerce any new drug, unless an approval of an application filed pursuant to subsection (b) or (j) is effective with respect to such drug.21 U.S.C. 355(a), FD&C Act section 505(a)

Section 301, at 21 U.S.C. 331, lists the prohibited acts. They are acts of commerce: introducing or delivering an adulterated, misbranded or unapproved article into interstate commerce, receiving and delivering it, manufacturing it, altering its labeling while it is held for sale, failing to register. The prohibited acts are acts of commerce, which is why FDA's warning letters in this market are addressed to sellers.

Why "research use only" on the label does not settle it

FDA does not read the disclaimer and stop. Its regulation on intended use, 21 CFR 201.128, says intent "may be shown by such persons' expressions, the design or composition of the article, or by the circumstances surrounding the distribution of the article," and the only place FDA's regulations define a "For Research Use Only" label is 21 CFR 809.10(c), which covers in vitro diagnostic products, not drugs. The agency's letters to peptide sellers in 2024, 2025 and 2026 follow one formula: the research-use-only label is noted, then set aside, because what the seller wrote and bundled shows what the product is for. That is why the answer to "can it be sold as research material" is yes, with a condition that the seller controls entirely. How this site draws that line is in what "research use only" actually means; what FDA reads on a website before it calls a research product a drug goes through the letters clause by clause.

Which peptides are approved drugs?

A handful of peptides are the active ingredient of an FDA-approved product, and for those the question "is it legal" has the ordinary answer: available by prescription, from a pharmacy, in the approved product. Drugs@FDA lists Ozempic (semaglutide, NDA 209637, approved December 5, 2017), Mounjaro (tirzepatide, NDA 215866, approved May 13, 2022), Egrifta (tesamorelin acetate, BLA 022505, approved November 10, 2010) and Vyleesi (bremelanotide acetate, NDA 210557, approved June 21, 2019). Geref (sermorelin acetate, NDA 020443) was approved in 1997 and is listed as discontinued.

An approval belongs to the product, not to the molecule. A research vial labelled "semaglutide" is not Ozempic, is not made under the approved application, and cannot be represented as equivalent to it. FDA's 2026 letters name "Semaglutide," "Tirzepatide" and "Tesamorelin" sold by research suppliers as unapproved new drugs for exactly that reason.

Can a pharmacy compound a research peptide?

Section 503A lets a state-licensed pharmacy or physician compound a drug from a bulk substance only if that substance has a USP or NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list. BPC-157, TB-500, KPV, MOTS-c, Semax, epitalon and the other peptides that dominate search traffic meet none of the three: their Category 2 nominations were withdrawn by the nominators on FDA's page dated April 22, 2026, which left them in no category, not in Category 1 and not on the bulks list, and as of September 21, 2026 FDA has published no rule after the July advisory committee vote. The full sequence is in Category 1, Category 2 and the 503A bulks list, and the difference between the three supply chains is in 503A, 503B and research-use-only.

Is there a state that bans peptides?

As of September 21, 2026 we have not found a state statute that prohibits research peptides as a class. That is a search, not a legal opinion, and it says nothing about what a state may do next. What does apply at state level is the ordinary machinery: pharmacy practice acts and boards of pharmacy, which license the 503A pharmacies that compounding runs through; medical practice acts, which govern what a clinic may prescribe; and consumer-protection statutes, which state attorneys general use against advertising claims. A research supplier is not a pharmacy and is not a clinic, and a clinic buying research material for use in people is on the wrong side of every one of those regimes at once.

Can peptides be imported?

Two mechanisms matter. The first is FDA's personal importation policy. The agency's own page opens with the sentence that answers the question:

In most circumstances, it is illegal for individuals to import drugs or devices into the U.S. for personal use because these products purchased from other countries often have not been approved by the FDA for use and sale in the U.S.FDA, Personal Importation, content current as of August 18, 2025

The discretionary exceptions on that page are written for a person with a serious condition and a physician, and they do not describe a research chemical order. The second mechanism is Import Alert 66-41, "Detention Without Physical Examination of Unapproved New Drugs Promoted In The U.S.," most recently revised on May 19, 2026. It lets FDA field divisions detain shipments from firms on its Red List without opening them, and puts the burden on the importer to prove the shipment "does not contain unapproved new drug products." The alert is not written about peptides, but its Red List includes firms whose peptide shipments were detained. The mechanics are in Import Alert 66-41 and research peptides.

Are peptides allowed in sport?

FDA status and sport status are separate systems, and athletes get caught between them. WADA's 2026 Prohibited List, in force from January 1, 2026, names BPC-157 as an example under S0, the class for substances "with no current approval by any governmental regulatory health authority for human therapeutic use," prohibited at all times. Section S2 names the GHRH analogues, secretagogues and growth factors that make up most of a hormones shelf, CJC-1295, sermorelin, tesamorelin, ipamorelin and TB-500 among them. Absence from the examples clears nothing, because S0 and the "similar biological effect" clauses are catch-alls. Placement by section is in WADA S0, S2 and where research peptides sit on the Prohibited List.

Everything in this catalog is sold as a chemical for laboratory research, with no use guidance, no calculators and no claims; that is the condition on which the "can it be sold as research material" row of the table above stays a yes, and the practice is described on the provenance page.

Sources

• 21 U.S.C. 321, Definitions, U.S. Code (House Office of the Law Revision Counsel), current
• 21 U.S.C. 331, Prohibited acts, U.S. Code, current
• 21 U.S.C. 355, New drugs, U.S. Code, current
• 21 U.S.C. 802, Definitions (Controlled Substances Act), U.S. Code, current
• 21 CFR 201.128, Meaning of "intended uses", govinfo, 2024 edition
• 21 CFR 809.10, Labeling for in vitro diagnostic products, govinfo, 2024 edition
• Warning letter to Gram Peptides, FDA, March 31, 2026
• Certain bulk drug substances for use in compounding that may present significant safety risks, FDA, content current as of April 22, 2026
• Bulk drug substances used in compounding under section 503A, FDA, content current as of May 14, 2026
• Personal importation, FDA, content current as of August 18, 2025
• Import Alert 66-41, FDA, revised May 19, 2026
• The 2026 Prohibited List, WADA, valid January 1, 2026